144 related articles for article (PubMed ID: 34004204)
21. Self-assembling protein nanocarrier for selective delivery of cytotoxic polypeptides to CXCR4
Rioja-Blanco E; Arroyo-Solera I; Álamo P; Casanova I; Gallardo A; Unzueta U; Serna N; Sánchez-García L; Quer M; Villaverde A; Vázquez E; Mangues R; Alba-Castellón L; León X
Acta Pharm Sin B; 2022 May; 12(5):2578-2591. PubMed ID: 35646535
[TBL] [Abstract][Full Text] [Related]
22. A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors.
Feuring-Buske M; Frankel AE; Alexander RL; Gerhard B; Hogge DE
Cancer Res; 2002 Mar; 62(6):1730-6. PubMed ID: 11912147
[TBL] [Abstract][Full Text] [Related]
23. Dynamic chemotherapy-induced upregulation of CXCR4 expression: a mechanism of therapeutic resistance in pediatric AML.
Sison EA; McIntyre E; Magoon D; Brown P
Mol Cancer Res; 2013 Sep; 11(9):1004-16. PubMed ID: 23754844
[TBL] [Abstract][Full Text] [Related]
24. Dissecting the role of the CXCL12/CXCR4 axis in acute myeloid leukaemia.
Ladikou EE; Chevassut T; Pepper CJ; Pepper AG
Br J Haematol; 2020 Jun; 189(5):815-825. PubMed ID: 32135579
[TBL] [Abstract][Full Text] [Related]
25. Targeting primary acute myeloid leukemia with a new CXCR4 antagonist IgG1 antibody (PF-06747143).
Zhang Y; Saavedra E; Tang R; Gu Y; Lappin P; Trajkovic D; Liu SH; Smeal T; Fantin V; De Botton S; Legrand O; Delhommeau F; Pernasetti F; Louache F
Sci Rep; 2017 Aug; 7(1):7305. PubMed ID: 28779088
[TBL] [Abstract][Full Text] [Related]
26. Selective depletion of metastatic stem cells as therapy for human colorectal cancer.
Céspedes MV; Unzueta U; Aviñó A; Gallardo A; Álamo P; Sala R; Sánchez-Chardi A; Casanova I; Mangues MA; Lopez-Pousa A; Eritja R; Villaverde A; Vázquez E; Mangues R
EMBO Mol Med; 2018 Oct; 10(10):. PubMed ID: 30190334
[TBL] [Abstract][Full Text] [Related]
27. Synthetic CXCR4 Antagonistic Peptide Assembling with Nanoscaled Micelles Combat Acute Myeloid Leukemia.
Meng J; Ge Y; Xing H; Wei H; Xu S; Liu J; Yan D; Wen T; Wang M; Fang X; Ma L; Yang Y; Wang C; Wang J; Xu H
Small; 2020 Aug; 16(31):e2001890. PubMed ID: 32608185
[TBL] [Abstract][Full Text] [Related]
28. CXCR4 inhibitors selectively eliminate CXCR4-expressing human acute myeloid leukemia cells in NOG mouse model.
Zhang Y; Patel S; Abdelouahab H; Wittner M; Willekens C; Shen S; Betems A; Joulin V; Opolon P; Bawa O; Pasquier F; Ito M; Fujii N; Gonin P; Solary E; Vainchenker W; Coppo P; De Botton S; Louache F
Cell Death Dis; 2012 Oct; 3(10):e396. PubMed ID: 23034331
[TBL] [Abstract][Full Text] [Related]
29. Rational engineering of a human GFP-like protein scaffold for humanized targeted nanomedicines.
Álamo P; Cedano J; Conchillo-Sole O; Cano-Garrido O; Alba-Castellon L; Serna N; Aviñó A; Carrasco-Diaz LM; Sánchez-Chardi A; Martinez-Torró C; Gallardo A; Cano M; Eritja R; Villaverde A; Mangues R; Vazquez E; Unzueta U
Acta Biomater; 2021 Aug; 130():211-222. PubMed ID: 34116228
[TBL] [Abstract][Full Text] [Related]
30. CXCR4 chemokine receptor signaling induces apoptosis in acute myeloid leukemia cells via regulation of the Bcl-2 family members Bcl-XL, Noxa, and Bak.
Kremer KN; Peterson KL; Schneider PA; Meng XW; Dai H; Hess AD; Smith BD; Rodriguez-Ramirez C; Karp JE; Kaufmann SH; Hedin KE
J Biol Chem; 2013 Aug; 288(32):22899-914. PubMed ID: 23798675
[TBL] [Abstract][Full Text] [Related]
31. Nanomicelles co-loading CXCR4 antagonist and doxorubicin combat the refractory acute myeloid leukemia.
Zhang M; Ge Y; Xu S; Fang X; Meng J; Yu L; Wang C; Liu J; Wen T; Yang Y; Wang C; Xu H
Pharmacol Res; 2022 Nov; 185():106503. PubMed ID: 36241000
[TBL] [Abstract][Full Text] [Related]
32. Fluorescent Dye Labeling Changes the Biodistribution of Tumor-Targeted Nanoparticles.
Álamo P; Pallarès V; Céspedes MV; Falgàs A; Sanchez JM; Serna N; Sánchez-García L; Voltà-Duràn E; Morris GA; Sánchez-Chardi A; Casanova I; Mangues R; Vazquez E; Villaverde A; Unzueta U
Pharmaceutics; 2020 Oct; 12(11):. PubMed ID: 33105866
[TBL] [Abstract][Full Text] [Related]
33. A CXCR4 antagonist leads to tumor suppression by activation of immune cells in a leukemia-induced microenvironment.
Han AR; Lee JY; Kim HJ; Min WS; Park G; Kim SH
Oncol Rep; 2015 Dec; 34(6):2880-8. PubMed ID: 26398122
[TBL] [Abstract][Full Text] [Related]
34. Dual Targeting of Acute Leukemia and Supporting Niche by CXCR4-Directed Theranostics.
Habringer S; Lapa C; Herhaus P; Schottelius M; Istvanffy R; Steiger K; Slotta-Huspenina J; Schirbel A; Hänscheid H; Kircher S; Buck AK; Götze K; Vick B; Jeremias I; Schwaiger M; Peschel C; Oostendorp R; Wester HJ; Grigoleit GU; Keller U
Theranostics; 2018; 8(2):369-383. PubMed ID: 29290814
[TBL] [Abstract][Full Text] [Related]
35. Anti-Tumor and Immune Enhancing Activities of Rice Bran Gramisterol on Acute Myelogenous Leukemia.
Somintara S; Leardkamolkarn V; Suttiarporn P; Mahatheeranont S
PLoS One; 2016; 11(1):e0146869. PubMed ID: 26752299
[TBL] [Abstract][Full Text] [Related]
36. A targeting delivery system for effective genome editing in leukemia cells to reverse malignancy.
Ren XH; Xu C; Li LL; Zuo Y; Han D; He XY; Cheng SX
J Control Release; 2022 Mar; 343():645-656. PubMed ID: 35157940
[TBL] [Abstract][Full Text] [Related]
37. Malignant progenitors from patients with CD87+ acute myelogenous leukemia are sensitive to a diphtheria toxin-urokinase fusion protein.
Frankel AE; Beran M; Hogge DE; Powell BL; Thorburn A; Chen YQ; Vallera DA
Exp Hematol; 2002 Nov; 30(11):1316-23. PubMed ID: 12423685
[TBL] [Abstract][Full Text] [Related]
38. Impact of CXCR4 inhibition on FLT3-ITD-positive human AML blasts.
Jacobi A; Thieme S; Lehmann R; Ugarte F; Malech HL; Koch S; Thiede C; Müller K; Bornhäuser M; Ryser M; Brenner S
Exp Hematol; 2010 Mar; 38(3):180-90. PubMed ID: 20035824
[TBL] [Abstract][Full Text] [Related]
39. Variable cytotoxicity of diphtheria toxin 388-granulocyte-macrophage colony-stimulating factor fusion protein for acute myelogenous leukemia stem cells.
Feuring-Buske M; Frankel A; Gerhard B; Hogge D
Exp Hematol; 2000 Dec; 28(12):1390-400. PubMed ID: 11146161
[TBL] [Abstract][Full Text] [Related]
40. Enhanced Anti-Leukemic Effects through Induction of Immunomodulating Microenvironment by Blocking CXCR4 and PD-L1 in an AML Mouse Model.
Hwang HS; Han AR; Lee JY; Park GS; Min WS; Kim HJ
Immunol Invest; 2019 Jan; 48(1):96-105. PubMed ID: 30204524
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]